Sernova has entered into a preclinical research collaboration on drug delivery with AstraZeneca, with the aim of evaluating the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells.
Sernova’s Cell Pouch System as an implantable and scalable medical device that forms a natural environment in the body for the long-term survival and function of therapeutic cells. Those cells release necessary proteins or factors missing from the body to treat chronic diseases, including insulin-dependent diabetes.
AstraZeneca aims to use the Sernova Cell Pouch System as a potential platform for integration with its cell therapies. Under the terms of the agreement, AstraZeneca will lead and completely fund development of the cell technologies and pre-clinical activities in conjunction with Sernova. Any therapeutic applications found could lead to subsequent product development activities between the two companies.
To read more, CLICK HERE.
